Concepedia

D Hagins

DH

Statistics

Publications

3

Citations

156

H-Index

3

Active since

2017

Affiliations

Janssen (Belgium)(Current)

D Hagins is an author at Janssen (Belgium) specializing in pharmacotherapy, clinical trials, and protease inhibitors.

Top concepts

Publications per year

2017–2019

3

Publications

3

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

Chloe Orkin, Jean‐Michel Molina, Eugènia Negredo et al. · The Lancet HIV · 2017 · 96 citations

, , +9

Switching to coformulated rilpivirine (<scp>RPV</scp>), emtricitabine (<scp>FTC</scp>) and tenofovir alafenamide from either <scp>RPV</scp>,<scp> FTC</scp> and tenofovir disoproxil fumarate (<scp>TDF</scp>) or efavirenz, <scp>FTC</scp> and <scp>TDF</scp>: 96‐week results from two randomized clinical trials

D Hagins, Chloe Orkin, ES Daar et al. · HIV Medicine · 2018 · 47 citations · Full text

Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials

Erkki Lathouwers, Eric Wong, Kimberley Brown et al. · AIDS Research and Human Retroviruses · 2019 · 13 citations · Full text

1–3 of 3